JP2024514182A5 - - Google Patents

Info

Publication number
JP2024514182A5
JP2024514182A5 JP2023563061A JP2023563061A JP2024514182A5 JP 2024514182 A5 JP2024514182 A5 JP 2024514182A5 JP 2023563061 A JP2023563061 A JP 2023563061A JP 2023563061 A JP2023563061 A JP 2023563061A JP 2024514182 A5 JP2024514182 A5 JP 2024514182A5
Authority
JP
Japan
Prior art keywords
mrna
vaccine according
antigenic polypeptide
encoding
respiratory viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514182A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024497 external-priority patent/WO2022221335A1/en
Publication of JP2024514182A publication Critical patent/JP2024514182A/ja
Publication of JP2024514182A5 publication Critical patent/JP2024514182A5/ja
Pending legal-status Critical Current

Links

JP2023563061A 2021-04-13 2022-04-12 呼吸器ウイルス組み合わせワクチン Pending JP2024514182A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163174463P 2021-04-13 2021-04-13
US63/174,463 2021-04-13
US202163175011P 2021-04-14 2021-04-14
US63/175,011 2021-04-14
US202163241959P 2021-09-08 2021-09-08
US63/241,959 2021-09-08
US202263322121P 2022-03-21 2022-03-21
US63/322,121 2022-03-21
PCT/US2022/024497 WO2022221335A1 (en) 2021-04-13 2022-04-12 Respiratory virus combination vaccines

Publications (2)

Publication Number Publication Date
JP2024514182A JP2024514182A (ja) 2024-03-28
JP2024514182A5 true JP2024514182A5 (cg-RX-API-DMAC10.html) 2025-04-17

Family

ID=81449216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563061A Pending JP2024514182A (ja) 2021-04-13 2022-04-12 呼吸器ウイルス組み合わせワクチン

Country Status (5)

Country Link
US (1) US20240216500A1 (cg-RX-API-DMAC10.html)
EP (1) EP4322993A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024514182A (cg-RX-API-DMAC10.html)
AU (1) AU2022258335A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022221335A1 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
EP4642481A2 (en) * 2022-12-29 2025-11-05 Popvax Private Limited Multitarget vaccines and therapeutics
TW202438672A (zh) * 2023-01-31 2024-10-01 美商亞克圖羅斯醫療公司 四價流感疫苗之方法及組成物
CN121419787A (zh) * 2023-06-28 2026-01-27 赛诺菲巴斯德有限公司 多价流感mRNA疫苗
WO2025186719A1 (en) * 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
WO2026003577A1 (en) * 2024-06-25 2026-01-02 Popvax Private Limited Multisubunit hepacivirus vaccines and therapeutics

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
US20090104226A1 (en) * 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
SG10201408164XA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
WO2012104820A1 (en) * 2011-02-04 2012-08-09 Pfizer Inc. Compositions for canine respiratory disease complex
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
DE20164728T1 (de) * 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
KR20190093816A (ko) * 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
WO2021239880A1 (en) * 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
CN112546211A (zh) * 2020-10-23 2021-03-26 嘉晨西海(杭州)生物技术有限公司 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法

Similar Documents

Publication Publication Date Title
JP2024513999A5 (cg-RX-API-DMAC10.html)
JP7817257B2 (ja) mRNAワクチンを送達するための脂質ナノ粒子
US11771653B2 (en) Lipid nanoparticles for delivering mRNA vaccines
JP2024503698A5 (cg-RX-API-DMAC10.html)
EP4226938A2 (en) Coronavirus vaccine
JP6185548B2 (ja) インフルエンザワクチンの製造方法
JP2011504486A5 (cg-RX-API-DMAC10.html)
CN116322758A (zh) 基于核酸的组合疫苗
JPH11500409A (ja) ワクチン組成物用アジュバント
JP2009539965A5 (cg-RX-API-DMAC10.html)
RU2015132962A (ru) Иммуногенные композиции на основе вируса гриппа и их применение
TW201427686A (zh) 改良之疫苗組成物及使用方法
US11878055B1 (en) Coronavirus vaccine
JP2015500854A5 (cg-RX-API-DMAC10.html)
WO2024191860A2 (en) Nucleic acid influenza vaccines and respiratory virus combination vaccines
US12208136B2 (en) Coronavirus vaccine
Chaparian et al. A virion-based combination vaccine protects against influenza and SARS-CoV-2 disease in mice
JP2024015475A (ja) コロナウイルスワクチン
JP2009514839A5 (cg-RX-API-DMAC10.html)
CN121038810A (zh) 针对冠状病毒感染、流行性感冒感染和/或rsv感染的组合疫苗
CN116650633A (zh) 冠状病毒疫苗
US20240366747A1 (en) Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
JP2011524372A (ja) インフルエンザワクチン接種のための新規ペプチドアジュバント
Jangra et al. Sterilizing immunity against SARS-CoV-2 infection in mice by a single-shot and modified imidazoquinoline TLR7/8 agonist-adjuvanted recombinant spike protein vaccine
TW202539697A (zh) 冠狀病毒疫苗